AVITA Medical Reports 18% Revenue Growth to $21.7 Million in Q2 2026

AVITA Medical, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $21.7 million, an 18% increase from $18.4 million in the same period last year. The growth was primarily driven by increased sales of its RECELL products and the introduction of the RECELL GO mini device, which targets smaller wounds. The company recorded a net loss of $7.7 million for the quarter, a 23% improvement compared to a net loss of $9.9 million in the prior year. For the first half of 2026, total revenues reached $41.0 million, up 11% from $36.9 million in the first half of 2025, with a net loss of $18.3 million, also a 23% reduction from $23.8 million in the previous year.

In terms of operational metrics, AVITA Medical's gross profit margin improved slightly to 81.9% from 81.2% year-over-year, attributed to a favorable product mix and lower volume discounts. The company reported a decrease in total operating expenses by 6% to $24.6 million for the quarter, driven by reductions in sales and marketing expenses, as well as general and administrative costs. The company’s employee headcount remained stable, with no significant changes reported in staffing levels.

Strategically, AVITA Medical has made significant moves to enhance its market position. The company entered into a ten-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to maintain a supply of RECELL for emergency situations, which could yield up to $25.5 million in potential revenue. Additionally, the company has expanded its international footprint, receiving regulatory approvals for the RECELL GO device in Australia and New Zealand, which supports its distributor-led commercialization strategy in those markets.

Despite the positive revenue growth, AVITA Medical faces challenges, including an accumulated deficit of $426.7 million as of June 30, 2026, and ongoing concerns regarding its ability to continue as a going concern. The company has indicated that it may require additional liquidity to sustain operations over the next twelve months, particularly in light of its debt obligations and historical negative cash flows. The company has entered into a $60 million credit facility to bolster its financial position, with $50 million drawn at closing and an additional $10 million available subject to revenue milestones. Looking ahead, AVITA Medical aims to increase market penetration in U.S. burn centers and expand the adoption of its products while navigating the complexities of the healthcare reimbursement landscape.